Navigation Links
Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field
Date:11/9/2009

WESTON, Mass., Nov. 9 /PRNewswire/ -- Groundbreaking articles in current issues of Journal of Opioid Management, for the first time explore, in depth, the emergence of cannabinoid medicine, its challenges for health care providers and its potential benefits for patients.

In these important articles, University of Washington authors, Sunil Aggarwal, PhD who is a member of the prestigious Medical Scientist Training Program and who conducted the article's research and Gregory T. Carter, MD, nationally recognized expert in the field of pain management, lead their team in taking a fresh look at all aspects of cannabinoid medicines, including the cannabinoid botanical marijuana, from the historical perspective and clinical evidence base for its use to the legal ramifications. In the second article, they offer a chart review examination of the treatment with medical cannabis of 139 chronic pain patients in the state of Washington.

As the authors point out, there is a near complete absence of education about cannabinoid medicine at any level of medical training despite the fact the Institute of Medicine concluded, after reviewing relevant scientific literature including dozens of works documenting marijuana's therapeutic value, that nausea, appetite loss, pain, and anxiety are all afflictions of wasting and all can be mitigated by the drug safely and with minimal toxicity. The research also shows that cannabinoid medicines have particular application for patients intolerant or refractory of opioid therapies for pain management.

The authors conclude that while cannabis is neither a miracle drug nor the answer to everyone's ills, the evidence suggests that physicians and medical students should make an extra effort to educate themselves in the art and science of cannabinoid medicine.

To purchase a reprint of Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions Sunil K. Aggarwal, PhD; Gregory T. Carter, MD, MS; Mark D. Sullivan, MD, PhD; Craig ZumBrunnen, PhD; Richard Morrill, PhD; Jonathan D. Mayer, PhD click this link http://tinyurl.com/ydqwtd2

To purchase a reprint of Characteristics of patients with chronic pain accessing treatment with medical cannabis in Washington State Sunil K. Aggarwal, PhD, MD Candidate; Gregory T. Carter, MD, MS; Mark D. Sullivan, MD, PhD; Craig ZumBrunnen, PhD; Richard Morrill, PhD; Jonathan D. Mayer, PhD click this link http://tinyurl.com/y9yk9zq .

Journal of Opioid Management, a professional, peer-reviewed publication is designed to meet the challenge faced by physicians as they prescribe powerful, quality-of-life enhancing painkillers to their patients. Filling a long standing gap in medical literature, it addresses all aspects of opioid use and safe management and does so at a time when the federal spotlight has been switched on to the rising problem of abuse and addiction tied to these prescription painkillers.

Journal of Opioid Management has become the unchallenged journal of record for those in the field today. For more information about the journal, visit http://www.opioidmanagement.com . To subscribe to the online edition please visit http://ejournal.opioidmanagement.com or call the circulation department at 781-899-2702 ext 108.

    Contact: Richard A. Devito, Jr.
    Journal of Opioid Management
    781-899-2702 Ext. 107
    radjr@pnpco.com

SOURCE Journal of Opioid Management


'/>"/>
SOURCE Journal of Opioid Management
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
2. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
3. IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
4. Asthmatx Presents Impact of Bronchial Thermoplasty on Allergy Practices at ACAAI Annual Meeting
5. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
6. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
7. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
8. Watson to Present at Credit Suisse Healthcare Conference
9. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
10. Cantel Medical Corp. to Present at the Sidoti Emerging Growth Research Institutional Investor Forum
11. BD to Present at Investor Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... 23, 2016 Global Paclitaxel Market ... profiles 12 companies and the Paclitaxel analysis in this ... the industry and its players. This is ... nature, details the current state of the industry while ... classifications, applications and industry chain structure. The Paclitaxel market ...
(Date:5/23/2016)... 2016 Clarifying Vision - Prospects ... and Vision Care What can be expected ... to grow at the fastest rates? This visiongain ... data, trends, opportunities and prospects. ,Our ... the most lucrative areas in the industry and the ...
(Date:5/23/2016)... 2016 Gamida Cell, a leader ... cancer and orphan genetic diseases, announced today it has ... from the Israel Innovation Authority (formerly the Office of ... and Industry. The mission of the Israel Innovation Authority ... including science and technology, while stimulating economic growth. ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... May 24, 2016 , ... ... of communication enabled solutions and managed services today announced a strategic partnership ... enterprise contact center market. , Altura, one of Avaya’s largest Platinum Business ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of ... will ever be totally eliminated, many human performance problems can be prevented. , How ...
(Date:5/24/2016)... ... May 24, 2016 , ... Regenerative Medicine is being ... adult stem cell therapy technology, protocols and patient results as have been achieved with ... become a more accessible standard of care for patients worldwide. , As the Medical ...
(Date:5/24/2016)... NY (PRWEB) , ... May 24, 2016 , ... ... treatment for physical disease or injury that focuses on repairing the musculoskeletal and ... , With an emphasis on functional restoration, NYDNRehab began providing treatments for physical ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
Breaking Medicine News(10 mins):